Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.
暂无分享,去创建一个
Lawrence A Leiter | P. McFarlane | E. Schiffrin | A. Logan | R. Hegele | L. Magee | S. Daskalopoulou | K. Zarnke | G. Benoît | P. Hamet | S. Rabkin | R. Gilbert | S. Lear | M. Hill | K. Lavoie | V. Woo | R. Tsuyuki | A. Pipe | K. Dasgupta | S. Bacon | L. Cloutier | J. Grégoire | T. Campbell | R. Padwal | K. McBrien | D. Rabi | P. Lindsay | A. Milot | M. Ruzicka | K. Burns | E. Burgess | N. Campbell | R. Feldman | J. Kaczorowski | P. Oh | G. Moe | Mukul Sharma | S. Coutts | M. Lamarre-Cliche | S. Tobe | J. Howlett | Charlotte A. Jones | G. Tremblay | D. Drouin | G. Prasad | J. Boulanger | G. Gubitz | G. Dresser | S. Hiremath | A. Côté | K. Nerenberg | A. Fournier | J. Feber | A. Leung | S. Butalia | K. Harris | M. Nakhla | M. Gelfer | P. Bolli | D. Mclean | Karen C. Tran | S. Grover | R. Herman | S. E. Gryn | R. Lewanczuk | L. Poirier | G. Honos | G. Kline | P. Selby | M. Gupta | L. Trudeau | M. Vallée | P. Sivapalan | S. Penner | J. Dionne | Debra J Reid | M. Khara | T. Wilson | G. Moullec | Ally Prebtani | K. Tran | Milan Khara | Charlotte A Jones | M. Hill
[1] Meilin Liu. Chinese expert consensus on the diagnosis and treatment of hypertension in the elderly (2017) , 2018, Aging medicine (Milton (N.S.W)).
[2] S. Gosselin,et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. , 2018, CJEM.
[3] S. Rabkin. Considerations in Understanding the Coronary Blood Flow- Left Ventricular Mass Relationship in Patients with Hypertension , 2016, Current cardiology reviews.
[4] D. Wood,et al. The Impact of Left Ventricular Mass on Diastolic Blood Pressure Targets for Patients With Coronary Artery Disease. , 2016, American journal of hypertension.
[5] Lenore J Launer,et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.
[6] Jackson T. Wright,et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.
[7] F. McAlister,et al. Epidemiology of Hypertension in Canada: An Update. , 2016, The Canadian journal of cardiology.
[8] P. McFarlane,et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.
[9] S. Yusuf,et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.
[10] A. Jamalian,et al. Lifestyle Modifications to Prevent and Control Hypertension. , 2016, Iranian journal of kidney diseases.
[11] F. Messerli,et al. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. , 2016, Journal of the American College of Cardiology.
[12] M. Woodward,et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.
[13] Isla Mackenzie,et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.
[14] Anne Forster,et al. Cluster Randomized Controlled Trial , 2015, Stroke.
[15] J. Kostis,et al. Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects , 2015, Hypertension.
[16] L. Brewster,et al. Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality: Systematic Review and Meta-Analysis , 2015, Hypertension.
[17] Faha,et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. , 2014, Circulation.
[18] E. McGlynn,et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. , 2013, Mayo Clinic proceedings.
[19] Martin McKee,et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.
[20] M. Woodward,et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. , 2013, The New England journal of medicine.
[21] Simon L Bacon,et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.
[22] H. Parise,et al. Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients: A Matched Cohort Study , 2013, Hypertension.
[23] Alan D. Lopez,et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[24] W. Elliott,et al. What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.
[25] K. Eagle,et al. The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients , 2012, Circulation.
[26] Lawrence A Leiter,et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. , 2012, The Canadian journal of cardiology.
[27] B. Sherrill,et al. Single‐Pill vs Free‐Equivalent Combination Therapies for Hypertension: A Meta‐Analysis of Health Care Costs and Adherence , 2011, Journal of clinical hypertension.
[28] G. Mancia,et al. Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice , 2011, Hypertension.
[29] Simon L Bacon,et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. , 2011, The Canadian journal of cardiology.
[30] M. Tremblay,et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades , 2011, Canadian Medical Association Journal.
[31] J. Banegas,et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.
[32] Michelle E. Kho,et al. AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.
[33] S. Bangalore,et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.
[34] C. Cannon,et al. What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial , 2010, Circulation.
[35] R. Lanzman,et al. Fibromuscular dysplasia in living renal donors: still a challenge to computed tomographic angiography. , 2010, European journal of radiology.
[36] L. Trinquart,et al. Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia: A Systematic Review and Meta-Analysis , 2010, Hypertension.
[37] Simon L Bacon,et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2010, The Canadian journal of cardiology.
[38] Alexander G Logan,et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy , 2009 .
[39] M. Vandervoort,et al. A Simplified Approach to the Treatment of Uncomplicated Hypertension: A Cluster Randomized, Controlled Trial , 2009, Hypertension.
[40] G. Bakris,et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.
[41] A. Lumsden,et al. The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. , 2008, Journal of vascular surgery.
[42] D. Goff,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[43] Lawrence A Leiter,et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2008, The Canadian journal of cardiology.
[44] Daniel W. Jones,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[45] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[46] Lawrence A Leiter,et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2007, The Canadian journal of cardiology.
[47] G. Mancia,et al. Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.
[48] E. Schiffrin,et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. , 2006, The Canadian journal of cardiology.
[49] Lawrence A Leiter,et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. , 2006, The Canadian journal of cardiology.
[50] F. McAlister. The Canadian Hypertension Education Program--a unique Canadian initiative. , 2006, The Canadian journal of cardiology.
[51] R. Collins,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.
[52] Alexander G Logan,et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. , 2005, The Canadian journal of cardiology.
[53] S. Textor. Pitfalls in Imaging for Renal Artery Stenosis , 2004, Annals of Internal Medicine.
[54] J. V. van Engelshoven,et al. Accuracy of Computed Tomographic Angiography and Magnetic Resonance Angiography for Diagnosing Renal Artery Stenosis , 2004, Annals of Internal Medicine.
[55] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[56] J. Laragh,et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.
[57] J. Olin,et al. Fibromuscular dysplasia. , 2004, The New England journal of medicine.
[58] O. Shoheiber,et al. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. , 2003, Congestive heart failure.
[59] N J Wald,et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.
[60] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[61] B. Davis,et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). , 2002, Journal of clinical hypertension.
[62] E. Schiffrin,et al. The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. , 2002, The Canadian journal of cardiology.
[63] E. Schiffrin,et al. The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. , 2002, The Canadian journal of cardiology.
[64] M. Mauro,et al. Incidence of donor renal fibromuscular dysplasia: does it justify routine angiography? , 2002, Transplantation.
[65] F. McAlister,et al. The 2000 Canadian recommendations for the management of hypertension: part two--diagnosis and assessment of people with high blood pressure. , 2001, The Canadian journal of cardiology.
[66] R. Hirose,et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. , 2000, Radiology.
[67] L. Appel,et al. Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. , 1999, Hypertension.
[68] C. Champagne,et al. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. , 1999, Journal of the American Dietetic Association.
[69] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[70] J. Riehl,et al. Renal artery stenosis: evaluation with colour duplex ultrasonography. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[71] G. Bray,et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.
[72] W. Kannel. Blood pressure as a cardiovascular risk factor: prevention and treatment. , 1996, JAMA.
[73] J. Olin,et al. The Utility of Duplex Ultrasound Scanning of the Renal Arteries for Diagnosing Significant Renal Artery Stenosis , 1995, Annals of Internal Medicine.
[74] G. T. Shaw,et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. , 1989, Radiology.
[75] K. Mettinger. Fibromuscular dysplasia and the brain. II. Current concept of the disease. , 1982, Stroke.
[76] O. Salvatierra,et al. Results and significance of angiography in potential kidney donors. , 1979, Radiology.
[77] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[78] Simon L Bacon,et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2014, The Canadian journal of cardiology.
[79] Lawrence A Leiter,et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.
[80] E. Schiffrin,et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. , 2010, The Canadian journal of cardiology.
[81] D. Wald,et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .
[82] E. Schiffrin,et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. , 2009, The Canadian journal of cardiology.
[83] E. Schiffrin,et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. , 2006, The Canadian journal of cardiology.
[84] E. Schiffrin,et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. , 2005, The Canadian journal of cardiology.
[85] E. Schiffrin,et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. , 2004, The Canadian journal of cardiology.
[86] F. McAlister,et al. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. , 2004, The Canadian journal of cardiology.
[87] J. Olin,et al. Fibromuscular dysplasia. , 2012, Circulation.
[88] A. Logan,et al. The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. , 2004, The Canadian journal of cardiology.
[89] Orton,et al. EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .
[90] R B Haynes,et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.